HIBT Lab! Immunai: Noam Solomon

According to the CDC, 6 in 10 adults in the U.S. have a chronic disease like cancer or diabetes. Meanwhile, the process for discovering new drug treatments is critically expensive and inefficient. About 90% of drug candidates fail to gain FDA approval; the average cost to develop a new drug is over $1 billion; and testing can take over 10 years.

Noam Solomon is on a mission to change this. His company, Immunai, is using artificial intelligence to create an atlas of the human immune system. 

This week on How I Built This Lab, Guy talks with Noam about how Immunai’s immune system mapping is accelerating the development of new personalized drug therapies. Plus, Noam shares how Immunai’s culture of ‘not knowing’ drives scientific innovation. 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.